Cue Biopharma (NASDAQ:CUE) is a clinical‐stage biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on the development of programmable cellular immunotherapies for the treatment of cancer and autoimmune diseases. The company’s proprietary platform is designed to selectively deliver cytokine signals to antigen‐specific T cells via engineered T cell receptor‐cytokine signaling complexes, with the goal of enhancing immune responses against disease while minimizing off‐target effects.
The company’s lead candidate, CUE-101, is an IL-2/IL-12 cytokine‐receptor complex engineered to stimulate tumor‐specific T cells in patients with solid tumors. Additional pipeline programs include CUE-102 and CUE-103, each programmed to target different tumor antigens or viral antigens, opening possibilities in oncology and chronic infection settings. Cue Biopharma’s modular approach enables rapid reprogramming for new targets, leveraging a platform licensed from Argonne National Laboratory.
Founded in 2016, Cue Biopharma was established to translate basic immunology concepts into novel therapies that offer precision control of the immune system. Under the leadership of President and Chief Executive Officer Sridhar Natarajan, the company has advanced multiple candidates into preclinical and clinical studies, building a team of scientists and clinicians with expertise in immuno‐oncology, molecular biology, and translational medicine.
Cue Biopharma operates primarily in the United States, collaborating with academic institutions, research hospitals, and industry partners to support its clinical development programs. The company’s efforts are focused on advancing its pipeline through regulatory milestones and into later‐stage clinical trials, with the long‐term aim of delivering safer, more effective immunotherapies to patients in need.
